



SenzaGen and RIFM expand collaboration on the safe use of fragrances with GARD™skin Dose-Response

Lund, March 4, 2021

SenzaGen and the Research Institute for Fragrance Materials (RIFM) have expanded their collaboration on the safe use of fragrance materials to evaluate the dosage at which a fragrance may induce an allergic response. Under the collaboration agreement, SenzaGen will receive an initial grant from RIFM of SEK 0.6 million to test several substances from RIFM with GARD™skin Dose-Response, a novel test for this application. The agreement runs through 2021.

RIFM is an international scientific non-profit organization based in the United States supporting the safe use of fragrance ingredients in consumer products. RIFM's Fragrance Ingredient Safety Assessments provide the International Fragrance Association (IFRA) with the scientific basis for developing standards for the safe use of aromatic components by the perfume industry.

"We are very proud of RIFM's continued trust in us and that our most recently launched test GARD™skin Dose-Response may contribute to progress in terms of sustainability and ethics in the testing market. With its strong position and broad scientific expertise, RIFM helps promote new technology and knowledge in the cosmetics and consumer product industry. RIFM's cooperation with us confirms GARD technology's strength and that it meets critical needs in these and our other prioritized industries. Access to more detailed information on skin sensitizing substances is important for companies developing products," says Axel Sjöblad, CEO of SenzaGen.

"We look forward to our continued collaboration with SenzaGen to evaluate GARD™skin Dose-Response as we refine our understanding of several fragrance ingredients. Identifying the dosage at which a fragrance may induce sensitization is a need that fragrance industry stakeholders have expressed for a long time. This project demonstrates our commitment to non-animal testing methods and supports our mission to provide the fragrance industry with data that meets internationally-recognized scientific standards," says Mihwa Na, PhD, Senior Scientist at RIFM.

Since 2020, SenzaGen and RIFM have been collaborating on the continued development of an application that can assess whether fragrance materials could induce skin allergies when exposed to sunlight (photosensitization).

For more information, please contact:

Axel Sjöblad, CEO, SenzaGen AB

Email: axel.sjoblad@senzagen.com | Mobile: +46 705 35 93 51

Mihwa Na, Senior Scientist, RIFM

Email: mna@rifm.org | Phone: +1.201.689.8089 ext. 108



About RIFM

Established in 1966, the Research Institute for Fragrance Materials (RIFM) generates, analyzes, evaluates, and distributes data to provide a scientific basis for the safe use of fragrances. RIFM has compiled the most comprehensive, worldwide source of toxicology data, literature, and general information on fragrance and flavor raw materials. RIFM's fragrance ingredient safety assessment program draws from its comprehensive database of over 70,000 references and more than 135,000 human health and environmental studies.

RIFM assesses the safety of fragrance ingredients by the most current, internationally accepted guidelines—and has done so since its founding. The Expert Panel for Fragrance Safety, an independent, international team of researchers and academics with no ties to the fragrance industry, reviews all of RIFM's work before RIFM submits it for peer-reviewed publication in a reputable scientific journal. RIFM makes all of its published, peer-reviewed work—current and historical—available for free at [fragrancematerialsafetyresource.elsevier.com](https://www.elsevier.com/locate/fragrancematerialsafetyresource).

About us

SenzaGen is a Swedish biotech company that provides state-of-the-art non-animal tests for assessing a substance's allergenicity. The GARD® test method combines genomic data from human cells with machine learning for a unique capability to identify and analyze whether a chemical could cause allergic reactions on the skin or in the respiratory tract. With excellent predictivity, GARD® meets needs in several industries and helps companies develop, produce and deliver safer, ethical and more sustainable products. GARD® tests are performed in SenzaGen's GLP-approved lab and by select partners in Europe and the US. SenzaGen has its headquarters in Lund, Sweden and a subsidiary in the US. For more information, please visit: www.senzagen.com.

SenzaGen is listed on Nasdaq Stockholm First North (ticker: SENZA), and FNCA Sweden AB, +46(0)8-528 00 399, info@fnca.se, is the company's Certified Adviser.

Attachments

[SenzaGen and RIFM expand collaboration on the safe use of fragrances with GARD™skin Dose-Response](#)